Core Viewpoint - The Nanjing Municipal Market Supervision Administration is enhancing the intellectual property protection capabilities of local medical device companies to support their international market expansion and innovation development [1][3]. Group 1: Training and Participation - A second phase of practical training on intellectual property protection for medical device companies was organized, involving over 20 representatives from listed and key export companies, as well as personnel from intellectual property law firms and service agencies [1]. - The training included site visits to key export companies, such as Nanjing Shuangwei Biomedical Technology Co., Ltd. and Nanwei Medical Technology Co., Ltd., which have established significant international presence and innovation capabilities [1]. Group 2: Expert Insights - Experts provided insights on overseas trademark brand strategy and patent risk prevention for medical device companies, discussing strategies and methods for foreign intellectual property protection [2]. - The training covered a five-step strategy for brand building and addressed risks associated with overseas trademark layout, as well as typical cases of patent disputes in the medical device sector [2]. Group 3: Future Initiatives - The Nanjing Municipal Market Supervision Administration plans to continue optimizing training formats and content to align with the development trends of the medical device industry and the needs of companies, thereby supporting innovation and internationalization [3].

Investment Rating - The industry investment rating is "Overweight" indicating a positive outlook for the high-value medical consumables sector [1]. Core Insights - The sixth batch of national centralized procurement for high-value medical consumables was held on January 13, 2026, with 12 types of medical consumables included, resulting in 440 products from 202 companies being selected [1]. - The selection rules were optimized to ensure that clinically recognized and capable products were chosen, emphasizing a "de-involution" approach [2]. - The report highlights the long-term growth potential of the high-value consumables sector post-price reduction expectations, driven by an aging population and increasing surgical and diagnostic volumes [2]. Summary by Sections Procurement Results - The procurement included drug-coated balloons and urological intervention consumables, with a high selection rate: all 42 products from 32 companies in the drug-coated balloon category were selected, and 398 products from 170 companies in the urological intervention category were chosen [2]. - Specific products with unique functions were also selected, meeting clinical needs [2]. Selection Rules - The selection process ensured that products with high clinical recognition and strong supply capabilities were prioritized [2]. - A pricing mechanism was introduced to reflect clinical value, avoiding a simple lowest-price selection method [2]. Company Analysis - Key companies involved include Lepu Medical, MicroPort Medical, and others, with notable price reductions in selected products compared to previous procurements [2]. - The report suggests monitoring companies such as Lepu Medical, MicroPort Medical, and others for investment opportunities [2]. Valuation Table - A valuation table is provided, showing market capitalization and projected profits for various companies, indicating their financial performance and P/E ratios for 2026 and 2027 [3].

Core Viewpoint - China is experiencing a significant growth in the microwave ablation market, driven by an aging population, increased health screenings, and supportive government policies, with the market expected to reach approximately 4.651 billion yuan in 2024, reflecting a year-on-year growth of 20.12% [1][7]. Industry Overview - Microwave ablation devices utilize microwave energy for localized thermal ablation of biological tissues, achieving treatment through high-frequency electromagnetic waves that cause rapid heating and cell necrosis [2][6]. Market Size - The market for microwave ablation devices in China is projected to grow significantly, with a market size of approximately 4.651 billion yuan in 2024, marking a 20.12% increase from the previous year [1][7]. Key Companies - The competitive landscape of the microwave ablation industry in China is characterized by domestic dominance, with Nanjing Yigao as a leading player, known for its cold-circulation microwave knife technology, which has set global industry standards [8]. - Sainuo Medical focuses on thyroid and breast ablation markets, achieving FDA breakthrough device certification for its innovative technologies [8][10]. Industry Development Trends 1. **Technological Advancements**: The industry is expected to focus on precision ablation and intelligent navigation, with innovations such as AI-assisted imaging and remote surgical platforms enhancing treatment capabilities [11][12]. 2. **Market Expansion**: The demand for microwave ablation devices is anticipated to grow due to rising cancer rates and the increasing acceptance of minimally invasive treatments, with a dual focus on grassroots and international markets [12][13]. 3. **Ecosystem Development**: Leading companies are transitioning from equipment suppliers to comprehensive solution providers, integrating technology, products, and services to create a closed-loop ecosystem in the industry [13].

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [5]. Core Insights - The medical device industry in China has a prominent supply chain advantage, with overseas markets expected to maintain rapid growth. The brain-computer interface (BCI) sector is at a critical turning point, likely to see demand release. AI medical applications are gradually becoming operational, poised to reshape the health market [3]. Summary by Relevant Sections Investment Recommendations - For the overseas medical device sector, recommended stocks include: United Imaging Healthcare, Nanwei Medical, Microelectronic Physiology, Guichuang Tongqiao, Yuyue Medical, and New Industry. Stocks to watch include: Jingfeng Medical, MicroPort Scientific, and Chuangli Medical [5]. - In the brain-computer interface sector, recommended stocks are: Lepu Medical, Weisi Medical. Stocks to watch include: Meihao Medical, Xiangyu Medical, Mcland, Xinwei Medical, Aipeng Medical, Chengyitong, Chuangxin Medical, and Botuo Bio [5]. - For the AI + device sector, recommended stocks are: Yuyue Medical, BGI Genomics, KingMed Diagnostics, and United Imaging Healthcare. Stocks to watch include: Dian Diagnostics [5]. Overseas Market Growth - The supply chain advantage of domestic medical devices is significant, with exports expected to grow rapidly. In the first three quarters of 2025, United Imaging Healthcare's overseas revenue increased by 41.97% year-on-year, becoming a crucial growth driver for the company. The company continues to expand its market share in key regions due to superior product performance and localized service capabilities. By December 2025, MicroPort Scientific's global cumulative order volume exceeded 160 units, with core products in endoscopy, orthopedics, and vascular intervention surpassing 230 units in total orders. In 2025, Jingfeng Medical achieved a breakthrough in multiple key global markets, leading to explosive growth in overseas orders [5]. Brain-Computer Interface Market - The brain-computer interface market is at a pivotal turning point, with anticipated demand release. China's "14th Five-Year Plan" explicitly suggests a forward-looking layout for future industries, promoting BCI as a new economic growth point. In December 2025, Elon Musk announced that Neuralink would begin large-scale production of BCI devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process. In January 2026, China's BCI company Strong Brain Technology announced it had completed a new round of financing of approximately 2 billion yuan, setting a record for the second-largest single financing in the field globally, following Neuralink. The funds will be used to accelerate core technology research and development, extreme engineering breakthroughs, and product scaling and mass production [5]. AI Medical Applications - AI medical applications are gradually becoming operational, with the potential to reshape the health market. In June 2025, Ant Group launched the AI Health Manager AQ, which was officially upgraded to "Antifufu" in December 2025. By January 2026, the "Antifufu" app had over 30 million monthly active users, with daily inquiries exceeding 10 million, 55% of which came from third-tier cities and below. In January 2026, Tempus AI reported preliminary revenue of approximately 1.27 billion USD for 2025, representing an 83% year-on-year increase, exceeding initial expectations. OpenAI announced the acquisition of the healthcare tech startup Torch to expand into the healthcare sector, while Google launched the next-generation open-source medical AI model MedGemma1.5 and released the open-source medical speech-to-text model MedASR [5].

（文章来源：证券日报） 证券日报网讯 1月12日，南微医学发布公告称，公司2026年第一次临时股东会审议通过《关于2026年度 日常关联交易额度预计的议案》。 ...

江苏新高的律师事务所 关于 南微医学科技股份有限公司 2026 年第一次临时股东会的 见证法律意见书 地址:南京市秦淮区龙蟠中路 419 号人保(南京)金融大厦 A 座 9、10 楼 电话: (025)84715285 传真: (025)84703306 邮编: 210001 江苏新高的律师事务所 2026年第一次临时股东会的见证法律; 江苏新高的律师事务所 关于南微医学科技股份有限公司 2026 年第一次临时股东会的见证法律意见书 苏高律股字[2026]第[0101]号 致:南微医学科技股份有限公司 江苏新高的律师事务所(以下简称"本所")接受南微医学科技股份有限公 司(以下简称"公司")委托,指派陶洪飞、陆佳佩律师(以下简称"本所律师") 出席公司 2026年第一次临时股东会(以下简称"本次股东会"),就本次股东 会的合法性进行见证并出具法律意见书。 本法律意见书依据《中华人民共和国公司法》(以下简称"《公司法》")、 《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规 则》(以下简称"《规则》")等相关法律、法规和规范性文件以及《南微医学 科技股份有限公司章程》(以下简称"《公司章程 ...

证券代码：688029 证券简称：南微医学 公告编号：2026-001 南微医学科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 1 月 12 日 1、 公司在任董事9人，列席9人； 2、董事会秘书龚星亮出席本次会议；其他高管列席本次会议。 （二） 股东会召开的地点：南京江北新区药谷大道 199 号 1 号楼公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 132 | | --- | --- | | 普通股股东人数 | 132 | | 2、出席会议的股东所持有的表决权数量 | 104,285,733 | | 普通股股东所持有表决权数量 | 104,285,733 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 55.8855 | | 例（%） | ...

Core Viewpoint - The article highlights the growth and international expansion of Nanwei Medical, a leading Chinese medical device company specializing in endoscopic diagnosis and treatment, with a focus on innovation and market penetration in both domestic and international markets [1][8]. Group 1: Company Overview - Nanwei Medical, established over 20 years ago, focuses on endoscopic diagnosis and treatment, developing a wide range of innovative products including endoscopic instruments and microwave/radiofrequency ablation devices [1][5]. - The company has achieved significant market access, with its products approved in over 90 countries and regions, and aims for overseas revenue to account for 58% by the first half of 2025 [1][10]. Group 2: Leadership and Strategy - Li Changqing, the Executive President, transitioned from a technical role to management, emphasizing the importance of both scientific and entrepreneurial skills in driving the company's growth [4]. - The company has established a dual-market strategy, focusing on both domestic and international markets, with a particular emphasis on penetrating the U.S. and European markets [9][11]. Group 3: Product Innovation - Nanwei Medical aims to increase the proportion of innovative products to over 30% within the next 3-5 years, currently standing at 10-15% [8]. - The company has developed over 60 types of products in the endoscopic field, showcasing a comprehensive product line that meets various clinical needs [5][6]. Group 4: Financial Performance - For the first three quarters of 2025, Nanwei Medical reported revenues of 2.381 billion yuan, an 18.29% increase year-on-year, with a net profit of 509 million yuan, up 12.90% [8][10]. - The company has shown consistent revenue growth from 1.980 billion yuan in 2022 to an expected 2.755 billion yuan in 2024 [8]. Group 5: International Expansion - The company has made strategic acquisitions to enhance its direct sales channels in Europe, including the purchase of companies in Portugal and Switzerland, and plans to acquire a 51% stake in a Spanish company [11]. - The establishment of a production base in Thailand is aimed at cost reduction and supply chain diversification [12].

南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688029 证券简称：南微医学 南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 | 2026 | 年第一次临时股东会会议须知 3 | | --- | --- | | 2026 | 年第一次临时股东会议程 5 | | 2026 | 年第一次临时股东会议案 6 | | 议案 | 1《关于 2026 年度日常关联交易额度预计的议案》 6 | 2 南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 南微医学科技股份有限公司 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会 目录 南微医学科技股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会议 的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》《上市公司股东会规则》以及《南微医学科技股份有限公司章程》 （以下简称"《公司章程》"）《南微医学科技股份有限公司股东会议事规则》等相 关规定，南微医学科技股份有限公司（以下简称 ...

证券日报网讯 1月5日，南微医学在互动平台回答投资者提问时表示，公司经营情况请关注公司后续定 期公告。 （文章来源：证券日报） ...